Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis

American Journal of Kidney Diseases

Volumn 68, Issue 5, 2016, Pages 677-690

  Shepshelovich, Daniel ^a,b   Rozen Zvi, Benaya ^a,b   Avni, Tomer ^a,b   Gafter, Uzi ^a,b   Gafter Gvili, Anat ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

anemia; blood transfusion; chronic kidney disease (CKD); cideferron; dialysis; end stage renal disease (ESRD); erythropoiesis stimulating agent (ESA); ferric carboxymaltose; ferric gluconate; ferritin; ferumoxytol; haemoglobin; Hb response; Iron; iron dextran; iron sucrose; iron supplementation; isomaltoside; IV iron; oral iron; quality of life; safety; systematic review; transferrin saturation (TSAT)

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; MORTALITY; QUALITY OF LIFE; SUPPLEMENTATION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANEMIA; HUMANS; IRON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84994868786     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.04.018     Document Type: Article

References (47)

1. 1 Regidor, D.L., Kopple, J.D., Kovesdy, C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:4 (2006), 1181–1191.
2. 2 Hsu, C.Y., McCulloch, C.E., Curhan, G.C., Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:2 (2002), 504–510.
3. 3 Babitt, J.L., Lin, H.Y., Mechanisms of anemia in CKD. J Am Soc Nephrol 23:10 (2012), 1631–1634.
4. 4 Icardi, A., Paoletti, E., De Nicola, L., Mazzaferro, S., Russo, R., Cozzolino, M., Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 28:7 (2013), 1672–1679.
5. 5 Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2 (2012), 279–335.
6. 6 Kliger, A.S., Foley, R.N., Goldfarb, D.S., et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 62:5 (2013), 849–859.
7. 7 Locatelli, F., Bárány, P., Covic, A., et al., on behalf of the ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 28:6 (2013), 1346–1359.
8. 8 Tolkien, Z., Stecher, L., Mander, A.P., Pereira, D.I., Powell, J.J., Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One, 10(2), 2015, e0117383.
9. 9 Rozen-Zvi, B., Gafter-Gvili, A., Paul, M., Leibovici, L., Shpilberg, O., Gafter, U., Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 52:5 (2008), 897–906.
10. 10 Albaramki, J., Hodson, E.M., Craig, J.C., Webster, A.C., Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev, 1, 2012, CD007857.
11. 11 Susantitaphong, P., Alqahtani, F., Jaber, B.L., Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 39:2 (2014), 130–141.
12. 12 Macdougall, I.C., Bircher, A.J., Eckardt, K.U., et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 89:1 (2016), 28–39.
13. 13 Avni, T., Bieber, A., Grossman, A., Green, H., Leibovici, L., Gafter-Gvili, A., The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 90:1 (2015), 12–23.
14. 14 Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.cochrane-handbook.org.
15. 15 Schulz, K.F., Chalmers, I., Hayes, R.J., Altman, D.G., Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:5 (1995), 408–412.
16. 16 Stoves, J., Inglis, H., Newstead, C.G., A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16:5 (2001), 967–974.
17. 17 Aggarwal, H.K., Nand, N., Singh, S., Singh, M., Hemant, Kaushik, G., Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51 (2003), 170–174.
18. 18 Charytan, C., Qunibi, W., Bailie, G.R., Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100:3 (2005), c55–c62.
19. 19 Van Wyck, D.B., Roppolo, M., Martinez, C.O., Mazey, R.M., McMurray, S., A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68:6 (2005), 2846–2856.
20. 20 Agarwal, R., Rizkala, A.R., Bastani, B., Kaskas, M.O., Leehey, D.J., Besarab, A., A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26:5 (2006), 445–454.
21. 21 Spinowitz, B.S., Kausz, A.T., Baptista, J., et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19:8 (2008), 1599–1605.
22. 22 McMahon, L.P., Kent, A.B., Kerr, P.G., et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrol Dial Transplant 25:3 (2010), 920–926.
23. 23 Qunibi, W.Y., Martinez, C., Smith, M., Benjamin, J., Mangione, A., Roger, S.D., A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 26:5 (2011), 1599–1607.
24. 24 Nagaraju, S.P., Cohn, A., Akbari, A., Davis, J.L., Zimmerman, D.L., Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol, 14, 2013, 64.
25. 25 Macdougall, I.C., Bock, A.H., Carrera, F., et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29:11 (2014), 2075–2084.
26. 26 Pisani, A., Riccio, E., Sabbatini, M., Andreucci, M., Del Rio, A., Visciano, B., Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 30:4 (2015), 645–652.
27. 27 Kalra, P.A., Bhandari, S., Saxena, S., et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 31:4 (2016), 646–655.
28. 28 Agarwal, R., Kusek, J.W., Pappas, M.K., A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88:4 (2015), 905–914.
29. 29 Allegra, V., Mengozzi, G., Vasile, A., Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 57:2 (1991), 175–182.
30. 30 Fishbane, S., Frei, G.L., Maesaka, J., Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:1 (1995), 41–46.
31. 31 Macdougall, I.C., Tucker, B., Thompson, J., Tomson, C.R., Baker, L.R., Raine, A.E., A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:5 (1996), 1694–1699.
32. 32 Svara, F., Sulkova, S., Kvasnicka, J., Polakovic, V., Iron supplementation during erythropoietin therapy in patients on hemodialysis. Vnitr Lek 42:12 (1996), 849–852.
33. 33 Fudin, R., Jaichenko, J., Shostak, A., Bennett, M., Gotloib, L., Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 79:3 (1998), 299–305.
34. 34 Warady, B.A., Kausz, A., Lerner, G., et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19:6 (2004), 655–661.
35. 35 Michael, B., Trout, J.R., Horl, W.H., Volinn, W., Jorjensen, N., Dahl, N.V., Effectiveness of continuous low-dose intravenous ferric gluconate therapy for maintaining Hb and decreasing epoetin requirement in hemodialysis patients. [abstract] J Am Soc Nephrol, 18, 2007, 289A.
36. 36 Li, H., Wang, S.X., Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 26:2 (2008), 151–156.
37. 37 Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., Pereira, B.J., Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4:2 (2009), 386–393.
38. 38 Tsuchida, A., Paudyal, B., Paudyal, P., et al. Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Exp Ther Med 1:5 (2010), 777–781.
39. 39 Adhikary, L., Acharya, S., Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. J Nepal Med Assoc 51:183 (2011), 133–136.
40. 40 Wang, C., Graham, D.J., Kane, R.C., et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314:19 (2015), 2062–2068.
41. 41 Toblli, J.E., Di Gennaro, F., Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS One, 10(4), 2015, e0125528.
42. 42 Macdougall, I.C., Geisser, P., Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 7:1 (2013), 9–22.
43. 43 Rottembourg, J., Rostoker, G., [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice.]. Nephrol Ther 11:7 (2015), 531–542.
44. 44 Minutolo, R., Liberti, M.E., Garofalo, C., et al. [Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease]. G Ital Nefrol 32:5 (2015), 1–10.
45. 45 Wong, G., Howard, K., Hodson, E., Irving, M., Craig, J.C., An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrol Dial Transplant 28:2 (2013), 413–420.
46. 46 Bailie, G.R., Larkina, M., Goodkin, D.A., et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87:1 (2015), 162–168.
47. 47 Freburger, J.K., Ellis, A.R., Wang, L., et al. Comparative effectiveness of iron and erythropoiesis-stimulating agent dosing on health-related quality of life in patients receiving hemodialysis. Am J Kidney Dis 67:2 (2016), 271–282.